Order Article Reprints

Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, López-Pavía M, et al. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers. 2022; 14(9):2342. https://doi.org/10.3390/cancers14092342

Labrador, Jorge, David Martínez-Cuadrón, Adolfo de la Fuente, Rebeca Rodríguez-Veiga, Josefina Serrano, Mar Tormo, Eduardo Rodriguez-Arboli, Fernando Ramos, Teresa Bernal, María López-Pavía, and et al. 2022. "Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry" Cancers 14, no. 9: 2342. https://doi.org/10.3390/cancers14092342

Labrador, J., Martínez-Cuadrón, D., de la Fuente, A., Rodríguez-Veiga, R., Serrano, J., Tormo, M., Rodriguez-Arboli, E., Ramos, F., Bernal, T., López-Pavía, M., Trigo, F., Martínez-Sánchez, M. P., Rodríguez-Gutiérrez, J.-I., Rodríguez-Medina, C., Gil, C., Belmonte, D. G., Vives, S., Foncillas, M.-Á., Pérez-Encinas, M., ... on behalf of PETHEMA Group. (2022). Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers, 14(9), 2342. https://doi.org/10.3390/cancers14092342